Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eric Schadt
Icahn School of Medicine at Mount Sinai, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sema4
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Eric Schadt (a Co-Principal Investigator in this study) is the Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai and serves as the Chief Executive Officer for Sema4. Dr. Schadt receives financial compensation from Sema4 and has an equity interest in Sema4.
Sema4 is a for-profit company currently owned by the Icahn School of Medicine at Mount Sinai. The company integrates genetic testing and data analytics to improve diagnosis, treatment and prevention of disease. Sema4, Sema4 employees and the Icahn School of Medicine at Mount Sinai could benefit from the work carried out in this study.
Systems Biology based Proteogenomic Translator for Cancer Marker Discovery towards Precision Medicine
PROJECT NARRATIVE The goal of the proposed Proteogenomic Data Analysis Center is to elucidate proteogenomic complexity underlying tumors by employing network based systems learning on CPTAC proteomic/genomic data. Our team brings together extensive expertise in systems learning and proteomics data modeling. The success of this application will generate valuable resources on (1) high-confidence candidate biomarkers and drug targets; (2) new knowledge of cancer biology that involves integrated genomic, transcriptomic, and proteomic data; and (3) new bioinformatics tools that aid in the mining, visualization and interpretation of large-scale datasets.
Filed on July 01, 2019.
Tell us what you know about Eric Schadt's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Eric Schadt filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Eric Schadt | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sema4 | $550,000 - $599,999 |
| Eric Schadt | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sema4 | $150,000 - $199,999 |
| Eric Schadt | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sema4 | Value cannot be readily determined |
| Eric Schadt | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sema4 | Value cannot be readily determined |
| Eric Schadt | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sema4 | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.